Evidence map›Paper›PMID 33891195›Full record

ArticleEJNMMI physics2021

Human biodistribution and dosimetry of [

Christopher Cawthorne, Paul Maguire, Joel Mercier, David Sciberras, Kim Serdons, Guy Bormans, Jan de Hoon, Koen Van Laere, Michel Koole

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI physics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Christopher CawthorneNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Paul MaguireUCB Pharma, Braine l'Alleud, Belgium.
Joel MercierUCB Pharma, Braine l'Alleud, Belgium.
David SciberrasUCB Pharma, Braine l'Alleud, Belgium.
Kim SerdonsDivision of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Guy BormansLaboratory for Radiopharmaceutical Research, KU Leuven, Leuven, Belgium.
Jan de HoonCenter for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium.
Koen Van Laere *Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Michel Koole *Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium. michel.koole@uzleuven.be.ORCID http://orcid.org/0000-0001-5862-640X
KU Leuven · BEUCB Pharma (Belgium) · BE

Funding

FWO I001719N
6 · The paper itself

Abstract

rationale[

methodsSequential whole-body PET scans were performed in 3 healthy subjects for 2 h after injection of 254 ± 77 MBq [

results[

conclusionsA single IV administration of 370 MBq [

trial registrationEudraCT number: 2016-001190-32. Registered 16 March 2016, no URL available for phase 1 trials.

Indexed as

[11C]-UCB-JHuman biodistributionOLINDARadiation dosimetrySynaptic density

Identifiers

PMID33891195
PMCPMC8065069
OpenAlexW3152899558

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.